Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Thu, 15.05.2025
tonies SE
tonies delivers strong start to the year 2025 - first quarter with EUR 97.2m net revenue
Group revenue in Q1 increases by 22.1% YoY in constant currency (cc) driven by international expansion (+24.1% nominal to EUR 97.2m)
North America continues positive momentum with growth of 37.5% YoY (cc) (+42.4% nominal to EUR 39.7m)
DACH region revenue sli [ … ]
Thu, 15.05.2025
Douglas AG
Q2 2024/25 (January – March 2025)
DOUGLAS Group on track to reach guidance for FY 2024/25 - significantly improved net income
Q2 results impacted by volatile environment and negative calendar effects:
Group sales -2.0% (reported) to 939.0 million euros (like-for-like, “lfl”: -2.5%), stores -0.1% (lfl: -2.4%), E-Com -5.6%; excluding sold-off Dis [ … ]
Thu, 15.05.2025
Circus SE
Circus SE to be Included in the MSCI Global Micro Cap Index
First-time significant visibility among institutional investors, analysts, and strategists worldwide
Circus SE is the only German company to have its shares newly included in the MSCI Global Micro Cap Index this year
Anticipated global capital inflows driven by inclusion in numerous ETF [ … ]
Thu, 15.05.2025
Flughafen Wien AG
Flughafen Wien AG Generates Positive Results in Q1/2025:
Increase in passenger traffic, revenue and earnings
Passenger growth in Q1/2025: 7.9 million passengers in the Group (+4.6%)
Financial performance indicators in the first quarter of 2025: revenue up 7.4% to € 225.9 million, EBITDA rise of 2.2% to € 81.3 million, EBIT increase of 4.9% [ … ]
Thu, 15.05.2025
Deutsche Konsum REIT-AG
PRESS RELEASE
Deutsche Konsum REIT reports stable rental performance in the first half of 2024/2025 with a focus on refinancing
Finalisation of a restructuring plan to secure long-term balance sheet stability expected by end of August
Portfolio adjustments with a potential volume of EUR 350 to 450 million in order to reduce debt by the end of 2 [ … ]
Thu, 15.05.2025
Cantourage Group SE
Not for direct or indirect publication or distribution within or in the United States of America, Australia, Canada or Japan or any other jurisdiction where such publication or distribution would be unlawful. Please note the important information at the end of this announcement.
PRESS RELEASE
Cantourage achieves another record revenue: EUR 11.1 m [ … ]
Thu, 15.05.2025
AT&S Austria Technologie & Systemtechnik AG
AT&S increases revenue in a challenging market environment
Revenue 2024/25 increases to € 1,590 million
Sale of AT&S Korea leads to profit for the year of € 90 million
Cost optimization and efficiency program continued
Customer diversification successfully advanced
Quarterly rather than annual guidance due to current uncertainty [ … ]
Thu, 15.05.2025
thyssenkrupp nucera AG & Co. KGaA
thyssenkrupp nucera Improves Sales and Earnings in Second Quarter
Continued high revenue growth for the electrolysis specialist in the second quarter and first half of 2024/2025
Both thyssenkrupp nucera business areas, green hydrogen and chlor-alkali electrolysis, contributed to sales growth
Strong improvement in earnings thanks to high sales m [ … ]
Thu, 15.05.2025
Züblin Immobilien Holding AG
Ad hoc announcement pursuant Article 53 LR - Züblin Immobilien Holding AG
Zurich, 15 May 2025
Financial year 2024/25 was a successful one for Züblin. Net rental income rose significantly as a result of new lettings, while lower interest rates had a positive impact on the revaluation of our properties and on financial expenses. Active property manag [ … ]
Thu, 15.05.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
Q2 2025 revenues up 8% yoy to EUR 252m; increase of 10% yoy at constant currencies
Q2 2025 EBITDA margin of 28.6% as reported and 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 56% in Q2 2025
SCHOTT Pharma reaffirms FY 2025 guidance
SCHOTT Pharma [ … ]